← The Wire
AUPHNasdaq
Aurinia Pharmaceuticals Inc.
Pharmaceutical Preparations · CIK 1600620
Aurinia Pharmaceuticals delivers therapies for autoimmune diseases, including the FDA-approved LUPKYNIS for lupus nephritis
⚡ Elevated coverage
$2.03B
Market cap
$16.79
Last close
-2.5%
1D
-4.2%
5D
3.6M
Volume
Price · last 39 sessions+6.5%
May 4L $15.14 · H $18.62Jun 29
318
Total filings
Jun 4, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 4, 2026SC 13D/ASC 13D/AJun 4, 20268-KAcquisition / DispositionMay 11, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEF 14ADEF 14AApr 21, 20268-KMaterial Agreement · Reg FD DisclosureApr 3, 2026SC 13D/ASC 13D/AMar 25, 20268-KExecutive ChangeMar 23, 2026SC 13D/ASC 13D/AMar 3, 202610-K10-KFeb 26, 20268-KResults of OperationsFeb 26, 20268-KResults of OperationsNov 4, 202510-Q10-QNov 4, 202510-Q10-QJul 31, 20258-KResults of Operations · Company UpdateJul 31, 20258-KCompany UpdateJun 30, 20258-KExecutive Change · Bylaw AmendmentMay 15, 202510-Q10-QMay 12, 20258-KResults of OperationsMay 12, 2025DEFA14ADEFA14AApr 30, 2025DEFA14ADEFA14AApr 29, 2025DEF 14ADEF 14AApr 17, 202510-K10-KFeb 27, 20258-KResults of OperationsFeb 27, 202510-Q10-QNov 7, 20248-KExecutive Change · Results of OperationsNov 7, 2024SC 13DSC 13DSep 12, 20248-KExecutive Change · Bylaw AmendmentSep 12, 202410-Q10-QAug 1, 20248-KResults of OperationsAug 1, 20248-KShareholder VoteJun 14, 2024DEFA14ADEFA14AJun 4, 2024DEFA14ADEFA14AJun 4, 2024DEFA14ADEFA14AMay 3, 2024DEF 14ADEF 14AMay 3, 202410-Q10-QMay 2, 20248-KNew Debt / ObligationMay 2, 202410-K/A10-K/AApr 29, 20248-KExecutive ChangeFeb 29, 202410-K10-KFeb 15, 20248-KResults of Operations · Exit / Disposal CostsFeb 15, 2024SC 13GSC 13GFeb 14, 20248-KResults of OperationsJan 5, 202410-Q10-QNov 2, 20238-KResults of OperationsNov 2, 20238-KExecutive Change · Material AgreementSep 21, 20238-KExecutive ChangeAug 21, 202310-Q10-QAug 3, 20238-KResults of OperationsAug 3, 20238-KExecutive Change · Company UpdateJul 3, 20238-KShareholder VoteMay 17, 2023DEFA14ADEFA14AMay 8, 202310-Q10-QMay 4, 20238-KResults of OperationsMay 4, 2023DEFA14ADEFA14AMay 2, 2023DEFA14ADEFA14AApr 28, 2023DEF 14ADEF 14AApr 18, 20238-KReg FD DisclosureApr 5, 20238-KCompany UpdateMar 13, 202310-K10-KFeb 28, 20238-KResults of OperationsFeb 28, 2023SC 13GSC 13GFeb 7, 20238-KCompany UpdateJan 27, 20238-KResults of OperationsJan 9, 20238-KCompany UpdateJan 3, 202310-Q10-QNov 3, 20228-KResults of OperationsNov 3, 2022SC 13GSC 13GOct 28, 20228-KExecutive ChangeOct 21, 20228-KExecutive Change · Reg FD DisclosureSep 19, 202210-Q10-QAug 4, 20228-KResults of OperationsAug 4, 20228-KExecutive ChangeJul 15, 20228-KShareholder VoteMay 20, 202210-Q10-QMay 10, 20228-KResults of OperationsMay 10, 2022DEFA14ADEFA14AApr 18, 2022DEF 14ADEF 14AApr 18, 202210-K10-KFeb 28, 2022
Insider Activity
In the 90 days to Mar 3, 2026: 1 insider bought $12.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 3, 2026 | Tang KevinDirector | Buy | 184,208 | $14.22 | $2.6M |
| Mar 2, 2026 | Tang KevinDirector | Buy | 115,792 | $14.21 | $1.6M |
| Mar 2, 2026 | Tang KevinDirector | Buy | 83,561 | $14.33 | $1.2M |
| Feb 27, 2026 | Tang KevinDirector | Buy | 300,000 | $13.90 | $4.2M |
| Feb 27, 2026 | Tang KevinDirector | Buy | 214,839 | $14.12 | $3.0M |
| Feb 27, 2026 | Tang KevinDirector | Buy | 1,600 | $14.38 | $23K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 1 reputable article.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance